<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506051</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00041</org_study_id>
    <nct_id>NCT00506051</nct_id>
  </id_info>
  <brief_title>ZD6474(Vandetanib) + Alimta Combo Study</brief_title>
  <official_title>A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets)
      to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help
      control their symptoms and disease better than the chemotherapy alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the safety &amp; tolerability of ZD6474 when administered in combination w/Pemetrexed (Alimta) to patients w/locally advanced or metastatic NSCLC after failure of prior chemo, by assessment of AEs, vital signs, lab, ECG and physical exam.</measure>
    <time_frame>assessed at each visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacokinetics of ZD6474 and Pemetrexed when given in combination to patients with locally advanced or metastatic NSCLC after failure of prior chemotherapy, by assessment of appropriate pharmacokinetic (PK) parameters.</measure>
    <time_frame>assessed at each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Carcinoma</condition>
  <condition>Non-Small Cell Lung</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ZD6474 (vandetanib) 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ZD6474 (vandetanib) 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474 (vandetanib) 100mg</intervention_name>
    <description>once daily oral tablet</description>
    <arm_group_label>ZD6474 (vandetanib) 100mg</arm_group_label>
    <other_name>ZACTIMA™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>ZD6474 (vandetanib) 100mg</arm_group_label>
    <arm_group_label>ZD6474 (vandetanib) 300mg</arm_group_label>
    <other_name>Alimta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474 (vandetanib) 300mg</intervention_name>
    <arm_group_label>ZD6474 (vandetanib) 300mg</arm_group_label>
    <other_name>ZACTIMA™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed advanced or metastatic non-small cell lung cancer

          -  Failure of first-line chemotherapy

          -  1 or more measurable lesion by RECIST

        Exclusion Criteria:

          -  Previous chemotherapy or radiotherapy within 4 weeks

          -  Significant cardiac events, arrythmias or other cardiac conditions

          -  Unacceptable laboratory measurements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1428&amp;filename=CSR-D4200C00041.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1428&amp;filename=CSR-D4200C00041.pdf</url>
    <description>CSR-D4200C00041.pdf</description>
  </link>
  <reference>
    <citation>de Boer R, Humblet Y, Wolf J, Nogová L, Ruffert K, Milenkova T, Smith R, Godwood A, Vansteenkiste J. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2009 Mar;20(3):486-91. doi: 10.1093/annonc/mdn674. Epub 2008 Dec 16.</citation>
    <PMID>19088171</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>alimta</keyword>
  <keyword>vandetanib</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

